Find policies, billing codes, payers, states, and providers
Chronic Vertigo
Customize your policy alerts
Sign up for Aetna Policy 0238 alerts
Get alerted when Policy 0238 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and coverage of diagnostic tests, maneuvers (including canalith repositioning), vestibular rehabilitation, and select devices/procedures for chronic vertigo and Ménière's disease for Aetna members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Vestibular Rehabilitation (medically necessary conditions)
Vestibular rehabilitation is considered medically necessary when ALL of the following are met:
Up to 12 visits initially; up to 12 additional visits if evidence of clinically significant improvement
Canalith Repositioning Maneuvers for BPPV
Use of the Epley maneuver or the Semont maneuver for treatment of BPPV is considered medically necessary when BOTH of the following selection criteria are satisfied:
Epley and Semont are not effective in persons with certain central nervous system disorders; in those cases considered experimental/investigational.
Diagnostic Vestibular Testing
The following diagnostic tests are considered medically necessary (unless otherwise specified):
ENG and VNG are considered medically necessary for evaluation of vestibular symptoms and as alternatives to each other; other modalities listed are included as medically necessary for diagnosis/evaluation per policy.
Vestibular rehabilitation — patient selection
Clinical indications and utility information summarized from evidence discussed in this section:
VR should be performed by a licensed occupational or physical therapist; typical program duration 6–12 weeks, some patients (eg, PPPD) may require 3–6 months.
Diagnostic testing — modalities and evidence
Diagnostic testing information and limitations:
Dynamic posturography is evolving with insufficient high-quality evidence supporting its effectiveness for diagnosis or prognosis; SOT comprises 6 conditions with 20-second trials repeated 3 times and equilibrium scoring (0–100); MCT uses 3 perturbation intensities.
Coverage considerations and clinical stance
Coverage considerations summarized from evidence presented in this section:
Posterior semicircular canal occlusion
Surgical posterior semicircular canal occlusion — evidence summary and considerations
Candidate patients are those with disabling, intractable BPPV after failure of conservative maneuvers; impaired hearing in the contralateral ear is a relative contraindication and patients should be counseled regarding risk of permanent canal nonfunction and hearing loss.
Balance-assessment devices (Biosway, SBMA, BTrackS)
Balance-assessment devices and test reliability/validity summaries:
SBMA (smartphone accelerometer app) shows ceiling effects for double-leg stances and limited sensitivity compared with force-plate measures.
Practice trials and standardized protocol adherence recommended when using percentile rankings.
VEMP testing (cVEMP/oVEMP)
cVEMP and oVEMP diagnostic utility:
AAN gives Level C recommendations for certain VEMP uses in SCDS.
VEMP testing is most useful when part of a comprehensive evaluation and when other results are inconclusive.
Evidence summaries (no formal coverage criteria)
Standardized protocol adherence and documentation of practice trials recommended when reporting percentile rankings.
No formal payer coverage criteria provided; consider chair-based therapy when manual maneuvers fail or for complex/refractory BPPV, with recognition of limited evidence strength.
Vestibular rehabilitation is considered experimental and investigational for indications other than those explicitly listed as medically necessary in this policy. The policy lists several devices and procedures that are considered experimental/investigational, including the BalanceBack Intuitive VNG device, BTrackS (Balance Tracking System), Brainstem auditory evoked potentials (BAEPs), CHAMP testing, DizzyFix, dynamic posturography, Biodex BioSway, Epley Omniax repositioning chair, Meniett low-pressure pulse generator, and posterior semicircular canal occlusion (this list is not all-inclusive).
The policy identifies patient groups who are generally considered poor candidates for vestibular rehabilitation, including those with unstable or progressive lesions (for example, autoimmune inner ear disease), patients with endolymphatic hydrops/Ménière’s disease, those with perilymphatic fistula, and individuals whose vertigo is due to demyelinating disease, epilepsy, or migraine.
Because vestibular rehabilitation relies on exercise-based compensation, it is not appropriate for patients with an unstable or progressive lesion; such lesions indicate ongoing disease activity that may prevent sustained benefit from rehabilitation. The policy therefore states that these patients are generally not good candidates for VR and should be evaluated for alternative management.
Evidence supporting the BalanceBack Intuitive VNG device is lacking; the device is cleared for recording eye movements but there is insufficient data to support its use for active management of balance disorders. By contrast, evidence for BTrackS is primarily from a limited group of investigators and, while reporting concurrent validity and reliability, generalizability and methodological concerns limit firm conclusions about clinical utility.
Limitations of the BTrackS normative dataset and related studies include collection of data across multiple sites without direct oversight by authors, reliance on test-site adherence to standardized protocol (potential noncompliance), imbalanced sampling across age/sex groups, and limited geographic/socioeconomic representation. These factors reduce generalizability of the reported normative percentiles.
This Clinical Policy Bulletin provides a partial, general description of plan or program benefits and does not constitute a contract. Coverage determinations are made in accordance with individual plan provisions, and the bulletin may be updated or changed.
Computerized dynamic posturography and associated CPT codes (e.g., 92548, 92549) and several named balance-assessment systems (for example, Biodex BioSway, Balance Tracking System/BTrackS, and repositioning chairs such as the Epley Omniax) are identified in the policy as experimental/investigational and not established for the indications listed. These procedures/devices are therefore considered investigational for those indications.
The policy notes that computerized dynamic posturography is an evolving technology with insufficient evidence supporting its effectiveness for diagnosing balance disorders or for predicting or influencing prognosis. Health-technology assessments and CMS advisory conclusions cited in the policy support the view that prospective studies are needed to establish clinical utility.
Systematic reviews and randomized trials of positive pressure therapy (Meniett) for Ménière’s disease do not demonstrate consistent benefit. Multiple RCTs comparing the Meniett device with placebo found no significant difference in vertigo control in pooled analyses, and some analyses suggested worse hearing outcomes in the positive-pressure groups; overall, systematic reviews concluded there is no reliable evidence to justify routine use of the Meniett device.
Methodological limitations of BTrackS studies include small single-site study samples, heavy reliance on data from one investigative group, multisite normative data collection without direct oversight, potential protocol noncompliance at some test sites, sample imbalances across age/sex groups, and limited representation of geographic and socioeconomic diversity; these issues limit the strength and applicability of conclusions drawn from the BTrackS normative dataset.
The policy sections describe evidence reviews and coverage considerations but do not themselves create contractual obligations. The Clinical Policy Bulletin is intended to assist in administering plan benefits and is not a contract; actual coverage is determined by the member’s plan provisions and applicable benefit terms.
Coding
| 92531 | Spontaneous nystagmus, including gaze |
| 92533 | Caloric vestibular test, each irrigation (binaural, bithermal stimulation constitutes 4 tests) |
| 92534 | Optokinetic nystagmus test |
| 92537 | Caloric vestibular test with recording, bilateral; bithermal (ie, one warm and one cool irrigation in each ear for a total of four irrigations) |
| 92538 | Caloric vestibular test, monothermal (ie, one irrigation in each ear for a total of two irrigations) |
| 92541 | Spontaneous nystagmus test, including gaze and fixation nystagmus, with recording |
| 92542 | Positional nystagmus test, minimum of 4 positions, with recording |
| 92544 | Optokinetic nystagmus test, bidirectional, foveal or peripheral stimulation, with recording |
| 92545 | Oscillating tracking test, with recording |
| 92546 | Sinusoidal vertical axis rotational testing |
| 92650 | Auditory evoked potentials; screening with broadband stimuli, automated analysis |
| 92651 | Auditory evoked potentials; for hearing status determination, with interpretation |
| 92652 | Auditory evoked potentials; for threshold estimation at multiple frequencies |
| 92653 | Auditory evoked potentials; neurodiagnostic, with interpretation and report |
| 92517 | Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) |
| 92518 | Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; ocular (oVEMP) |
| 92519 | Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) and ocular (oVEMP) |
| No codes listed |
Provider Actions and Requirements
Verify prior auth for covered vestibular codes and selection-criteria dependency
Certain CPT and HCPCS codes for canalith repositioning maneuvers, vestibular diagnostic testing, and vestibular rehabilitation are covered only when the CPB selection criteria are met; providers should verify payer-specific prior authorization rules before submitting claims. Relevant covered codes include CPT 92532 and 95992 for maneuvers and a range of vestibular testing and rehabilitation codes (eg, 92531–92547, 99173, 97112, S9476).
No prior authorization requirements stated here
This section of the CPB does not state any explicit prior-authorization requirements; providers must consult the member’s plan or payer authorization rules for any applicable prior authorization processes.
Prior auth may be required for transtympanic micropressure (Meniett) therapy
Requests for transtympanic micropressure (Meniett) therapy may require prior authorization because use requires insertion of a tympanostomy tube and device-based therapy; document prior medical therapy failure and clinical rationale when seeking coverage.
- Micropressure use necessitates tympanostomy tube insertion with associated surgical risks
- Document prior failed medical therapy and rationale for device use
Obtain prior authorization for semicircular canal occlusion (recommended)
Prior authorization is recommended for surgical semicircular canal occlusion given its use as a surgical option for intractable BPPV and potential serious complications (including deafness and vestibular loss); obtain authorization and document prior conservative maneuvers and counseling on risks.
- Canal occlusion considered for intractable BPPV after failed maneuvers
- Potential complications include transient postoperative dizziness and rare permanent hearing or vestibular loss
No explicit prior authorization stated for repositioning-chair therapy
No explicit prior-authorization requirements are stated for repositioning-chair therapy in this CPB; evidence for these devices is limited to retrospective and observational studies without randomized trials.
- Repositioning chairs (Epley Omniax/TRV) evidence is low-quality and lacking RCTs
- Check payer rules if billing for chair-based procedures
Refer to main policy/plan documents for prior authorization rules
This excerpt does not specify comprehensive prior-authorization rules — providers should refer to the full Clinical Policy Bulletin and the member’s specific plan documents or payer authorization requirements for any additional prior authorization details.
Require failure of medical management before vestibular rehabilitation
Vestibular rehabilitation is considered medically necessary only after failure of medical management (for example, vestibular suppressant medications); document prior medical therapy attempts when requesting rehabilitation services.
- Eligibility includes symptoms > 6 months, confirmed vestibular disorder or prior ablative vestibular surgery, and failed medical management
- Initial authorization typically covers up to 12 visits; up to 12 additional visits may be allowed if clinically significant improvement is documented
Perform VR with licensed OT/PT and select appropriate candidates
Vestibular rehabilitation should be provided to appropriate candidates and performed by a licensed occupational or physical therapist with vestibular expertise; document supervised sessions and home exercise instruction.
- VR typically involves supervised instruction and a home exercise program lasting 6–12 weeks (some cases 3–6 months)
- Patients with unstable/progressive lesions, Meniere’s disease, perilymphatic fistula, demyelinating disease, epilepsy, or migraine are generally poor candidates
Use repositioning maneuvers and standard VR as preferred initial therapies
For BPPV and certain peripheral vestibular disorders, manual repositioning maneuvers (eg, Epley, Semont) and established vestibular rehabilitation are preferred first-line therapies before considering alternative devices or procedures.
- Epley/Semont indicated when Hallpike (Dix-Hallpike) is positive and symptoms have persisted ≥4 months
- Repositioning maneuvers more effective short-term than exercise-based VR for BPPV
Consider surgical canal occlusion only after failed repositioning maneuvers
Surgical occlusion of the posterior semicircular canal is described as an option for patients disabled by intractable BPPV after conservative maneuvers have failed; document prior conservative treatments and patient counseling on permanent canal nonfunction and hearing risk.
- Surgery renders the posterior canal permanently nonfunctional; transient postoperative hearing loss and dizziness are common, persistent hearing loss occurs in <5%
- Consider only after failure of repositioning maneuvers
Document symptom duration, diagnosis, prior surgery, and progress for VR
Vestibular rehabilitation claims require documentation that symptoms have persisted for more than 6 months, that a vestibular disorder is confirmed or the patient had prior ablative vestibular surgery, and evidence of clinical progress when requesting additional visits.
- Symptom duration > 6 months is required for medical necessity
- Initial authorization: up to 12 visits; additional up to 12 visits only with documented clinically significant improvement
Record tests and compare results to normative data (ENG/VNG, CDP)
ENG/VNG and dynamic posturography record objective eye movements or postural sway; test results must be compared with age-matched normative data and equilibrium scores computed for interpretation.
- ENG records corneal‑retinal potential differences; VNG records eye movements via infrared goggles
- Dynamic posturography computes equilibrium scores (0–100) compared with age-matched normals
Document diagnosis and ability or trial of VR (eg, PPPD)
Document the specific vestibular diagnosis (for example, PPPD) and evidence that the patient can participate in or has trialed vestibular rehabilitation exercises, including supervised sessions and home-exercise plans.
- Document diagnosis (eg, PPPD) and ability to perform exercise-based therapy
- Note supervised sessions and home exercise instructions in the medical record
Document informed consent for canal occlusion including hearing/vestibular risks
Obtain and document informed consent for semicircular canal occlusion that explains the risk of transient and rare persistent hearing and vestibular loss, prior conservative management attempts, and the permanence of canal nonfunction.
- Counsel on risk of deafness and loss of vestibular function reported in series
- Document prior failed conservative maneuvers and patient understanding of permanent canal nonfunction
Document protocol adherence and dataset limitations when reporting BTrackS results
When using BTrackS-derived percentile rankings, document adherence to the standardized BTrackS Balance Test protocol and note any deviations or practice trials because the normative dataset relied on site adherence and had collection limitations.
- Record protocol adherence and any practice trials or deviations
- Acknowledge limitations of normative dataset in documentation
Reference CPB and plan-specific provisions for documentation and coverage
Providers should consult the Clinical Policy Bulletin and the member’s specific plan provisions for documentation, coverage determination, and any payer-specific rules; the CPB is a partial description and not a contract.
No additional provider actions specified in this section
No specific provider actions are detailed in this CPB section; follow plan and payer requirements for administrative processes and clinical documentation.
Tympanostomy tube insertion is required for micropressure therapy; document surgical risks
Transtympanic micropressure therapy requires insertion of a tympanostomy tube; note associated surgical risks such as anesthesia complications, otorrhea, and tympano-sclerosis which may affect appropriateness and coverage decisions.
- Use requires tympanostomy tube insertion
- Document risks: anesthesia, otorrhea, tympano-sclerosis
BalanceBack VNG billed as a management tool may be denied
The BalanceBack Intuitive VNG device lacks evidence for use in management (rather than recording only); billing it as a management tool may lead to denial—use it only for diagnostic recording or document justification.
- BalanceBack VNG intended for recording and analysis of eye movements; not proven for management
- May be denied if billed as a management tool rather than diagnostic recording
No explicit provider actions stated in these chunks
No explicit provider actions are described in the referenced CPB chunks; follow payer instructions for claims and authorizations as applicable.
CPBs do not constitute coverage guarantees—use plan/payer documents
Clinical Policy Bulletins are a partial description of benefits and do not guarantee coverage; providers should use plan documents and payer authorization policies for final coverage determinations.
Definitions
Background
Vertigo is a symptom of vestibular dysfunction with multiple causes. Common etiologies discussed in the policy include peripheral inner-ear disorders such as benign paroxysmal positional vertigo (BPPV) — a mechanical disorder due to displaced canaliths — and Ménière’s disease (endolymphatic hydrops). Diagnostic maneuvers (e.g., Hallpike/Dix-Hallpike) and specific testing modalities (ENG/VNG, caloric testing, VEMP, and CDP components) are described in the background to support evaluation and management.
Key Metrics
Revision History
Policy last reviewed on 04/26/2023; content and clinical guidance were reaffirmed during this review.
Policy originally became effective on 05/07/1998.
Next scheduled policy review date set for 02/22/2024.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.